title: Targeting triple-negative breast cancer and high-grade ovarian carcinoma: refining BRCAness beyond BRCA1/2 mutations?
authors: Department of Medical Oncology, Institut régional du Cancer de Montpellier (ICM) - Val d'Aurelle, 208 rue des Apothicaires, 34298 Montpellier Cedex 5, France.
authors: William
authors: W
authors: Jacot
authors: Charles
authors: C
authors: Theillet
authors: Séverine
authors: S
authors: Guiu
authors: Pierre-Jean
authors: PJ
authors: Lamy
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D004249:DNA Damage / Q000187:drug effects; D005260:Female; D019398:Genes, BRCA1; D024522:Genes, BRCA2; D042822:Genomic Instability / Q000187:drug effects; D006801:Humans; D058990:Molecular Targeted Therapy; D009154:Mutation; D060787:Neoplasm Grading; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D064726:Triple Negative Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D000067856:Poly(ADP-ribose) Polymerase Inhibitors
keywords: 53BP1; BRCA1; breast cancer; methylation; ovarian cancer; targeted therapies